Klein 13.5. The Reboxetine page mentions this reaction in one paragraph. This page teaches the method.
While standard peroxyacid epoxidations (like MCPBA) yield racemic mixtures of epoxides from chiral or achiral alkenes, the Sharpless Asymmetric Epoxidation provides a powerful method to install an epoxide enantioselectively. Developed by K. Barry Sharpless, this reaction converts an allylic alcohol into an optically active epoxide with exceptional enantiomeric excess.
The Sharpless epoxidation relies on a precisely tuned catalytic reagent system composed of four components:
The choice of diethyl tartrate enantiomer controls the three-dimensional outcome of the epoxide:
To easily predict the major enantiomer without memorizing complex transition-state models: orient your allylic alcohol horizontally in the xy-plane with the hydroxyl ($\text{OH}$) group positioned in the lower-right quadrant.
* (-)-DET will always deliver the epoxide oxygen from the bottom (away from you / dashed).
* (+)-DET will always deliver the epoxide oxygen from the top (toward you / wedged).
The Sharpless epoxidation has a strict structural requirement: the substrate must be an allylic alcohol (an $\text{OH}$ group attached to a $\text{sp}^3$ carbon adjacent to the $\text{C}=\text{C}$ double bond).
Consider the asymmetric epoxidation of (E)-2-methyl-3-penten-2-ol:
As noted in our discussion of pharmaceutical targets, the Sharpless epoxidation is not just an academic exercise—it is a critical industrial tool.
During the enantioselective synthesis of reboxetine (a selective norepinephrine reuptake inhibitor used as an antidepressant), a key chiral epoxide building block is constructed using a Sharpless asymmetric epoxidation. Setting this single stereocenter with high enantiomeric purity early in the synthetic route ensures that the final drug molecule possesses the correct three-dimensional shape required for biological efficacy.